XML 45 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Disaggregation of revenue
Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
In thousandsYear Ended December 31, 2023
Products By Geographic AreaTotalU.S.Rest of World
Drug Revenues
Product Sales - Point-in-time$— $— $— 
License Fee – Over time2,338 — 2,338 
Total Drug Products2,338 — 2,338 
Concentrate Products
Product Sales – Point-in-time79,802 72,871 6,931 
License Fee – Over time1,472 1,472 — 
Total Concentrate Products81,274 74,343 6,931 
Net Revenue$83,612 $74,343 $9,269 
In thousandsYear Ended December 31, 2022
Products By Geographic AreaTotalU.S.Rest of World
Drug Revenues
Product Sales - Point-in-time$903 $561 $342 
License Fee – Over time256 — 256 
Total Drug Products1,159 $561 598 
Concentrate Products
Product Sales – Point-in-time69,162 62,715 6,447 
License Fee – Over time2,489 2,489 — 
Total Concentrate Products71,651 65,204 6,447 
Net Revenue$72,810 $65,765 $7,045 
Contract balances
The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.
In thousandsDecember 31, 2023December 31, 2022January 1, 2022
Accounts Receivable, net$10,901 $6,259 $5,913 
Contract Liabilities, which are included in deferred license revenue$521 $4,331 $8,157 
Summary of loss per share restated amounts The table below summarizes previously reported and restated amounts on a comparative basis.
Year Ended December 31,
2022
As Previously Reported:
Net Loss Per Share Attributable to Common Stockholders - Basic and Diluted$(1.89)
Weighted Average Number of Shares of Common Stock Outstanding - Basic and Diluted9,866,844 
As Restated:
Net Loss Per Share Attributable to Common Stockholders - Basic and Diluted$(1.31)
Weighted Average Number of Shares of Common Stock Outstanding - Basic and Diluted14,304,512 
Summary of potentially dilutive securities The following table includes the potential shares of common stock, presented based on amounts outstanding at each period end, that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
As of December 31,
20232022
Warrants to purchase common stock3,793,388 10,196,268 
Convertible Preferred Stock1,363,636 1,363,636 
Options to purchase common stock1,328,621 1,206,905 
Unvested restricted stock units258,885 125,000 
Unvested restricted stock awards891 891 
Total6,745,421 12,892,700 
Schedule of Basic and Diluted Net Loss Per Share
The following table presents the calculation of basic and diluted EPS:
Years Ended December 31,
20232022
Numerator:
Net Loss$(8,439)$(18,679)
Accretion of Series X Preferred Stock(150)— 
Net Loss Attributable to Common Stockholders$(8,589)$(18,679)
Denominator
Weighted Average Number of Shares of Common Stock Outstanding - Basic and Diluted23,322,915 14,304,512 
Net Loss Per Share Attributable to Common Stockholders - Basic and Diluted$(0.37)$(1.31)